BMEYE steps up expansion with €6m
This article was originally published in Clinica
Dutch noninvasive cardiovascular monitoring company BMEYE is picking up the pace of its commercialisation activities following a €6m investment boost. The funds were raised in a series B round and came from new investors Earlybird and 360 Capital Partners, as well as from existing BMEYE shareholders Life Sciences Partners and Techfund. Amsterdam-based BMEYE has been selling its first product, Nexfin, in Europe and the US since the device was CE marked and FDA-cleared in 2007. The Nexfin uses a finger sensor to produce beat-to-beat, noninvasive blood pressure and cardiac output data. The company said it will use the series B financing to launch new products and expand its sales channels.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.